View More Recent Stories

Jun 8, 2017 12:00PM Transgene: Combined General Meeting of June 8, 2017
Apr 25, 2017 12:00PM Transgene: €50.7 Million in Cash and Cash Equivalents as of March 31, 2017
Apr 25, 2017 01:30AM Transgene and Bristol-Myers Squibb Announce Clinical Research Collaboration to Evaluate TG4010 in Combination with Opdivo and Standard Chemotherapy in First Line Non-Small Cell Lung Cancer
Apr 25, 2017 01:30AM Transgene and Bristol-Myers Squibb Announce Clinical Research Collaboration to Evaluate TG4010 in Combination with Opdivo and Standard Chemotherapy in First Line Non-Small Cell Lung Cancer
Apr 24, 2017 11:45AM SillaJen and Transgene Announce the Enrollment of the First European Patient in Multinational Phase 3 Trial for Pexa-Vec in Advanced Liver Cancer
Apr 24, 2017 11:45AM SillaJen And Transgene Announce the Enrollment of the First European Patient in Multinational Phase 3 Trial For Pexa-Vec in Advanced Liver Cancer
Apr 19, 2017 12:00PM Marie Landel and Maya Said Nominated to Be Independent Members of Transgene’s Board of Directors
Apr 12, 2017 11:45AM Transgene and Institut Bergonié Start the Phase 2 Part of the METROmaJX Trial
Apr 10, 2017 12:00PM Transgene Announces Upcoming Investor Meetings and R&D Day
Mar 30, 2017 11:45AM Transgene Presents Very Promising New Immunology Data of its Next Generation Armed Oncolytic Virus at the AACR Annual Meeting in Washington, DC
Mar 20, 2017 12:35PM Major Achievements in 2016 Validate Transgene’s Strategy and Provide Promising Outlook for 2017
Mar 13, 2017 01:00PM First Patient Dosed in Phase 2 Trial Evaluating Transgene’s TG4010 in Combination With Opdivo® (Nivolumab) for 2nd Line Treatment of Metastatic Non-Small Cell Lung Cancer (NSCLC)
Feb 13, 2017 12:00PM Transgene and Léon Bérard Cancer Center Announce Dosing of the First Patient in a Phase 1 Immunotherapy Clinical Trial Evaluating the Intra-Tumoral Co-Administration of Pexa-Vec plus Ipilimumab (Yer
Jan 5, 2017 12:00PM Transgene Announces Financial Calendar for 2017
Dec 22, 2016 12:00PM Transgene Announces Upcoming Investor Events
Nov 14, 2016 12:00PM Transgene Presents Preclinical Results of TG1050, an HBV-targeted Immunotherapy, at AASLD 2016 Liver Meeting
Oct 28, 2016 01:10PM Transgene Announces Publication in OncoImmunology of Pre-Clinical Data Demonstrating Delivery of a Fully Functional Immune Checkpoint Inhibitor (ICI) with Anti-Tumor Efficacy by a New Generation of On
Oct 17, 2016 12:00PM First Patient Randomized in Multiple Dose Cohort of Phase 1/1b Trial with Transgene’s TG1050 in Chronic Hepatitis B Patients
Oct 5, 2016 12:00PM Transgene Presents Data on Improved Cytotoxic Activity of Oncolytic Viruses Expressing Intrabodies in Resistant Tumor Cell Lines
Sep 5, 2016 11:35AM Transgene Provides an Update on its Development Strategy and on its First Half-Year 2016 Financials
Sep 1, 2016 12:00PM Transgene Announces Participation at Upcoming Investor Events
Jul 21, 2016 12:00PM Transgene to Continue Phase 1/1b Study with TG1050 in Chronic Hepatitis B Patients on the Recommendation of the Trial’s Safety Review Committee
Jan 28, 2016 02:45AM EIB Lends EUR 20m to Transgene
Jan 6, 2016 09:00AM TransGaming and Visiware to Launch 'Hopper Arcade' on DISH
View More Recent Stories